Compare TARS & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARS | BBUC |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2020 | 2015 |
| Metric | TARS | BBUC |
|---|---|---|
| Price | $63.52 | $34.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $89.00 | $41.00 |
| AVG Volume (30 Days) | ★ 446.1K | 197.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $26.19 |
| 52 Week High | $85.25 | $38.25 |
| Indicator | TARS | BBUC |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 56.78 |
| Support Level | $61.24 | $33.67 |
| Resistance Level | $67.70 | $35.22 |
| Average True Range (ATR) | 3.19 | 0.81 |
| MACD | -0.40 | -0.00 |
| Stochastic Oscillator | 25.54 | 69.83 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.